VolitionRx Expands Nu.Q® NETs Assay Use in Hidradenitis Suppurativa
Event summary
- VolitionRx sponsors a symposium at the 15th EHSF Conference in Malta on February 5, 2026.
- Professor Evangelos J. Giamarellos-Bourboulis presents data on Nu.Q® NETs assay for HS patient management.
- Study shows Nu.Q® NETs can classify HS patients and guide treatment selection.
- Nu.Q® NETs assay is CE-Marked for clinical use in 30 European countries and the UK.
- Total Addressable Market for Nu.Q® NETs indications estimated at $3.8 billion.
The big picture
VolitionRx's expansion of its Nu.Q® NETs assay into Hidradenitis Suppurativa represents a strategic move into precision medicine for chronic diseases. The assay's ability to classify patients and guide treatment selection positions it as a key player in the growing biomarker-driven diagnostics market. With a $3.8 billion Total Addressable Market, the assay's success could drive significant revenue growth for VolitionRx, particularly as it seeks to expand into other chronic and acute conditions.
What we're watching
- Clinical Validation
- Whether Nu.Q® NETs can sustain its role in guiding treatment initiation and cessation across multiple chronic conditions.
- Market Expansion
- The pace at which VolitionRx can expand Nu.Q® NETs into other disease areas beyond HS.
- Regulatory Dynamics
- How the CE-Mark approval will influence adoption rates in Europe and potential regulatory pathways in other regions.
Related topics